STOCK TITAN

Merus N.V - MRUS STOCK NEWS

Welcome to our dedicated news page for Merus N.V (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merus N.V's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merus N.V's position in the market.

Rhea-AI Summary
Merus N.V. announces plans for transformative year in 2024 with phase 3 trials, BLA submissions, and ongoing clinical developments. Financial results show increased collaboration revenue, extended cash runway, and progress in key partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
earnings
-
Rhea-AI Summary
Merus N.V. (MRUS) announced that its CEO will participate in investor conferences on February 7th and 22nd, 2024. The webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
-
Rhea-AI Summary
Merus N.V. (Nasdaq: MRUS) announced updated interim clinical data on MCLA-129 from ongoing expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) at the European Society for Medical Oncology (ESMO) Asia Congress 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Merus N.V. (MRUS) announces the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website. The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Merus N.V. announced financial results for Q3 2023 and provided a business update. The company plans to submit potential BLA applications for its Zeno and petosemtamab programs. Clinical data for Zeno in NRG1+ NSCLC and PDAC show robust efficacy. The company also raised $172M in a public offering, with existing funds expected to support operations into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.4%
Tags
earnings
-
Rhea-AI Summary
Merus N.V. announced that its CEO, Bill Lundberg, will participate in two investor conferences: BMO Biopharma Spotlight Series: Oncology Day on November 8 and Stifel 2023 Healthcare Conference on November 14. The BMO conference will have a fireside chat with no live webcast, while the Stifel conference will have a live webcast. Archived presentations will be available on the company's website for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
conferences
Rhea-AI Summary
Merus N.V. announces interim clinical data for zenocutuzumab in NRG1+ cancer patients, showing promising results and potential for BLA submissions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
-
Rhea-AI Summary
Merus N.V. announces the acceptance of abstracts on bispecific antibodies MCLA-129 and zenocutuzumab for presentation at the ESMO Asia Congress 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Summary
Merus N.V. CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
Rhea-AI Summary
Merus N.V. announces the pricing of an underwritten public offering of 6,818,182 common shares at $22.00 per share, with an option for the underwriters to purchase an additional 1,022,727 common shares. The gross proceeds from the offering are expected to be approximately $150.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
offering
Merus N.V

Nasdaq:MRUS

MRUS Rankings

MRUS Stock Data

2.99B
42.23M
7.3%
91.36%
8.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Utrecht

About MRUS

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.